Limitations, agreements, and source contact

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma · Source last updated 2022-10-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

point Of Contact

email

astsao@mdanderson.org

organization

UT MD Anderson Cancer Center

phone

(713) 792-6363

title

Dr. Anne Tsao, MD- VP, Academic Affairs, CAO Office

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice